Medivir, Interim Report, 1 January - 30 September 2008

Medivir, Interim Report, 1 January - 30 September 2008

• Net sales were SEK 31.9 (80.8) m. In May, Medivir signed an additional
agreement with Tibotec Pharmaceuticals Ltd. on hepatitis C, triggering a SEK
46.2 m (EUR 5 m) payment. This amount has been allocated over the assessed
agreement term, with SEK 9.6 m recognized as revenue.
• The loss after tax amounted to SEK -102.4 (-138.1) m.
• Earnings per share were SEK -4.91 (-8.23).
• Cash flow from operating activities was SEK -30.4 (-129.6) m.
• Liquid assets as of 30 September were SEK 295.7 (264.0) m.


For more information, please contact:
Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292.